Peptides
MOTS-c explained: what the research says
What MOTS-c is, what it is studied for, why most evidence comes from animals, and what to know about safety, sport rules and FDA status.
MOTS-c comes up in almost every conversation about energy and peptides. Here is what it is, what researchers have found so far, and what is still unknown.
MOTS-c: a peptide from your mitochondria
Mitochondria are the small structures inside cells that turn food into usable energy. They carry their own DNA, separate from the DNA in the cell nucleus. In 2015, researchers reported that a short stretch of mitochondrial DNA codes for a 16-amino-acid peptide they named MOTS-c.
In mice, MOTS-c acted as a signal that affects how cells handle energy. It works through AMPK, a sensor cells use to balance energy supply and demand, and it changed how muscle used glucose. Some studies also find that MOTS-c levels in the body rise during exercise, which is why researchers study it alongside physical activity.
What MOTS-c research does not show
Most MOTS-c research is in cells and animals. It has not been shown to cause weight loss or improve fitness in people, and long-term safety in people is not established. If you are interested in weight care, GLP-1 programs are a separate, better-studied option to discuss with your provider.
Because MOTS-c is studied for glucose use, anyone who takes insulin or another medication that lowers blood sugar needs to tell their provider before starting.
At a glance
| MOTS-c | |
|---|---|
| What it is | A peptide coded by mitochondrial DNA |
| Studied for | Cellular energy and glucose use |
| Evidence in people | Limited |
| Sport rules | On the WADA Prohibited List |
| FDA status | Compounded, not FDA-approved |
Regulatory status
When a licensed pharmacy compounds a peptide, it prepares it for one patient on a prescription. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality. In 2026 the FDA removed MOTS-c from its list of compounding substances that raise significant safety concerns, but its policy on peptide compounding is still developing.
Who should avoid it
- People who are pregnant, breastfeeding or trying to conceive
- Anyone with active cancer or a history of cancer
- Athletes in tested sports, because MOTS-c is on the World Anti-Doping Agency Prohibited List
- Anyone under 18
- Anyone on insulin or blood sugar medication without their provider's approval
Possible side effects
Reported effects include injection-site redness, swelling or bruising, headache, nausea and tiredness. Allergic reactions are possible. Tell your provider about every medication and supplement you take.
How to get started
MOTS-c through Awesentials starts with a 10-minute online visit with a licensed provider, who decides whether it is appropriate for you.
Sources
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metab, 2015) | PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
- Compounding and the FDA: Questions and Answers | FDA
- The Prohibited List | World Anti-Doping Agency
This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
